Morepen Labs Q4 Performance: 69% Net Profit Rise and Revenue Growth in Medical Devices

NewsVoirGurugram (Haryana) [India], May 27: Morepen Laboratories Limited reported strong Q4 FY26 performance with net profit rising 69% YoY to Rs. 20 crore and gross revenue increasing 22% YoY to Rs. 472 crore. Revenue growth during the quarter was supported by export momentum and expansion in the Medical Devices business, while operational momentum strengthened toward the latter part of FY26.

Quarterly and Annual Highlights

• Gross revenue grew 22% YoY to Rs. 472 Cr in Q4 FY26
• Net profit increased 69% YoY to Rs. 20 Cr in Q4 FY26
• API business grew 17% in Q4 FY26
• Medical Devices business grew 31% in Q4 FY26
• FY26 standalone gross revenue crossed Rs. 1,700 Cr, up 8%
• Board proposes 10% dividend for FY26
• 4th consecutive USFDA inspection completed with NIL 483 observations
• Commercial production commenced under long-duration manufacturing program
• Capacity expansion underway from ~500 KL toward ~800 KL

Backed by its multi-year Rs. 825 crore / USD 91 million global CDMO mandate received in February 2026 from a leading global multinational, Q4 FY26 marked the commencement of commercial production under Morepen's long-duration manufacturing partnership program. The Company has completed validation batches and aligned initial supply schedules for phased delivery under the program, with supplies expected to commence shortly.

The quarter also witnessed continued investments toward manufacturing scale-up, regulated-market programs and Medical Devices expansion. EBITDA stood at Rs. 32 crore in Q4 FY26 compared to Rs. 33 crore in Q4 FY25, reflecting these growth investments. The Company believes these initiatives are intended to support operating leverage, margin expansion and long-term growth visibility over the coming quarters.

Commenting on the Company's strategic direction, Mr. Sushil Suri, Chairman & Managing Director, Morepen Laboratories Limited, said,